EX-99.1 2 bntx-ex991_7.htm EX-99.1 bntx-ex991_7.htm

Exhibit 99.1

 

BioNTech SE, Mainz, Germany

Annual General Meeting in Munich, Germany, 26 June 2020

 

Voting results - Overview - Only the German version is binding

 

 

Agenda Item 2

Approval of the actions of the Management Board - accepted

152,033,174

 

Number of shares for which valid votes were cast (= 63.826 % of the registered share capital)

152,015,170

 

Yes votes

 

99.988 % of the valid votes cast

18,004

 

No votes

 

0.012 % of the valid votes cast

Agenda Item 3

Approval of the actions of the Supervisory Board - accepted

73,516,708

 

Number of shares for which valid votes were cast (= 30.864 % of the registered share capital)

73,497,269

 

Yes votes

 

99.974 % of the valid votes cast

19,439

 

No votes

 

0.026 % of the valid votes cast

Agenda Item 4

Appointment of the auditor for the 2020 financial year - accepted

195,931,883

 

Number of shares for which valid votes were cast (= 82.256 % of the registered share capital)

195,927,278

 

Yes votes

 

99.998 % of the valid votes cast

4,605

 

No votes

 

0.002 % of the valid votes cast

Agenda Item 5

Amendment of the authorization to issue stock options - accepted

195,518,062

 

Number of shares for which valid votes were cast (= 82.082 % of the registered share capital)

195,449,670

 

Yes votes

 

99.965 % of the valid votes cast

68,392

 

No votes

 

0.035 % of the valid votes cast

Agenda Item 6

Expansion of options to exclude subscription rights for authorised capital - accepted

195,507,877

 

Number of shares for which valid votes were cast (= 82.078 % of the registered share capital)

195,492,290

 

Yes votes

 

99.992 % of the valid votes cast

15,587

 

No votes

 

0.008 % of the valid votes cast

Agenda Item 7

Amendments to the Articles of Association in connection with the invitation to and conduct of general meetings - accepted

195,487,103

 

Number of shares for which valid votes were cast (= 82.069 % of the registered share capital)

193,271,471

 

Yes votes

 

98.867 % of the valid votes cast

2,215,632

 

No votes

 

1.133 % of the valid votes cast

Agenda Item 8a

Approval of the conclusion of the domination agreement between the Company as controlling company and BioNTech Small Molecules GmbH as dependent company - accepted

195,511,012

 

Number of shares for which valid votes were cast (= 82.079 % of the registered share capital)

195,505,708

 

Yes votes

 

99.997 % of the valid votes cast

5,304

 

No votes

 

0.003 % of the valid votes cast

Agenda Item 8b

Approval of the conclusion of the domination agreement between the Company as controlling company and BioNTech IVAC GmbH as de-pendent company - accepted

195,510,926

 

Number of shares for which valid votes were cast (= 82.079 % of the registered share capital)

195,505,442

 

Yes votes

 

99.997 % of the valid votes cast

5,484

 

No votes

 

0.003 % of the valid votes cast

 


 

BioNTech SE, Mainz, Germany

Annual General Meeting in Munich, Germany, 26 June 2020

 

Voting results - Overview - Only the German version is binding

 

Agenda Item 8c

Approval of the conclusion of the domination agreement between the Company as controlling company and BioNTech Real Estate Holding GmbH as dependent company - accepted

195,510,844

 

Number of shares for which valid votes were cast (= 82.079 % of the registered share capital)

195,504,260

 

Yes votes

 

99.997 % of the valid votes cast

6,584

 

No votes

 

0.003 % of the valid votes cast

Agenda Item 8d

Approval of the conclusion of the domination and profit and loss transfer agreement between the Company as controlling company and JPT Peptide Technologies GmbH as dependent company - accepted

195,511,026

 

Number of shares for which valid votes were cast (= 82.079 % of the registered share capital)

195,503,722

 

Yes votes

 

99.996 % of the valid votes cast

7,304

 

No votes

 

0.004 % of the valid votes cast

Agenda Item 8e

Approval of the conclusion of the domination and profit and loss transfer agreement between the Company as controlling company and BioNTech Cell & Gene Therapies GmbH as dependent company - accepted

195,511,435

 

Number of shares for which valid votes were cast (= 82.079 % of the registered share capital)

195,504,552

 

Yes votes

 

99.996 % of the valid votes cast

6,883

 

No votes

 

0.004 % of the valid votes cast